SLC5A2 and liver dysplastic nodule: Na+-glucose cotransporter 2 (SGLT2) inhibitors are new and efficient drugs that have been studied in some clinical trials aiming to treat DN based on the effect of SGLT2 on glucose reabsorption in the early proximal tubule [9], which accounts for ∼ 97% of renal glucose reabsorption under normal glycemic conditions.